Munder Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Munder Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-2,090	Closed	-$689K	–	697
2014 Q1	$689K	Buy	+2,090	New	+$705K	0.01%	481

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Munder Capital Management's ICPT Position: Q2 2014 in Review

Munder Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2014, closing a stake of 2,090 shares — an estimated $689K sold.

Munder Capital Management first reported a position in ICPT in Q1 2014 and held it in 1 quarter. The position peaked at $689K in Q1 2014. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2014.

Munder Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
Munder Capital Management sold 2,090 Intercept Pharmaceuticals, Inc. shares in Q2 2014, an estimated $689K.
Munder Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
Munder Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $689K in Q1 2014.
167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2014.

Based on Munder Capital Management's 13F filing for Q2 2014, filed 6 Aug 2014.